Boston Scientific Corporation $BSX Shares Sold by S Bank Fund Management Ltd

Key Points

• S Bank Fund Management Ltd reduced its stake in Boston Scientific Corporation by 28.2%, now holding 9,939 shares valued at approximately $1.07 million.
• Analysts are optimistic, with BTIG increasing their price target from $127 to $132, while Oppenheimer upgraded the stock from "market perform" to "outperform."
• Boston Scientific reported a strong earnings performance, with $5.06 billion in revenue and $0.75 earnings per share for the last quarter, exceeding analyst expectations.

S Bank Fund Management Ltd lowered its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 28.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,939 shares of the medical equipment provider's stock after selling 3,907 shares during the quarter. S Bank Fund Management Ltd's holdings in Boston Scientific were worth $1,068,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $437,000. Tlwm boosted its holdings in shares of Boston Scientific by 0.8% in the second quarter. Tlwm now owns 14,520 shares of the medical equipment provider's stock valued at $1,560,000 after acquiring an additional 112 shares in the last quarter. Ritholtz Wealth Management boosted its holdings in shares of Boston Scientific by 3.5% in the second quarter. Ritholtz Wealth Management now owns 36,284 shares of the medical equipment provider's stock valued at $3,897,000 after acquiring an additional 1,225 shares in the last quarter. Harbour Investments Inc. boosted its holdings in shares of Boston Scientific by 17.3% in the second quarter. Harbour Investments Inc. now owns 6,308 shares of the medical equipment provider's stock valued at $678,000 after acquiring an additional 929 shares in the last quarter. Finally, Cypress Wealth Services LLC boosted its holdings in shares of Boston Scientific by 8.4% in the second quarter. Cypress Wealth Services LLC now owns 2,754 shares of the medical equipment provider's stock valued at $296,000 after acquiring an additional 214 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BSX shares. BTIG Research increased their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a report on Wednesday, October 1st. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $118.00 to $125.00 in a report on Monday, September 8th. Erste Group Bank cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Truist Financial raised their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a report on Wednesday, October 1st. Finally, Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and an average target price of $120.71.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $17,972,457 in the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 1.6%

BSX stock opened at $97.77 on Thursday. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market cap of $144.87 billion, a price-to-earnings ratio of 58.20, a PEG ratio of 2.32 and a beta of 0.61. The company has a 50 day moving average of $101.48 and a two-hundred day moving average of $101.77.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 EPS. The company's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.